modelR03DA07

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Theobromine
ATC code:R03DA07
route:oral
compartments:1
dosage:300mg
volume of distribution:0.82L
clearance:2.5ml/min/kg
other parameters in model implementation

Theobromine is a naturally occurring methylxanthine found in cacao beans, tea leaves, and some other plants. It is structurally related to caffeine and has mild stimulant, diuretic, and smooth muscle relaxant properties. Historically, theobromine has seen some use in respiratory medicine for its bronchodilator properties, but it is not commonly used or approved as a drug in modern clinical practice.

Pharmacokinetics

Estimated typical pharmacokinetic parameters for healthy adult humans based on available literature, as there are no well-established population PK models or detailed compartmental analyses in peer-reviewed sources specific to this drug.

References

  1. Zandvliet, AS, et al., & Beijnen, JH (2005). Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. Basic & clinical pharmacology & toxicology 96(1) 71–79. DOI:10.1111/j.1742-7843.2005.pto960111.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15667599

  2. Yesair, DW, et al., & Callahan, MM (1984). Human disposition and some biochemical aspects of methylxanthines. Progress in clinical and biological research 158 215–233. PUBMED:https://pubmed.ncbi.nlm.nih.gov/6396646

  3. Dorne, JL, et al., & Renwick, AG (2001). Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 39(7) 681–696. DOI:10.1016/s0278-6915(01)00005-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11397515

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)